Encodia, a San Diego firm developing DNA‑tagged peptide protein sequencing (ProteoCode), ceased operations late last year and filed an assignment for the benefit of creditors on Nov. 7, 2025, according to reports and a former employee post. The company is auctioning mass spectrometers, sequencers and liquid handlers. Encodia had raised roughly $75 million in prior rounds; its closure highlights volatility in the emerging single‑molecule/protein‑sequencing segment.